Human CCL13(Monocyte Chemotactic Protein 4) ELISA Kit

Name: Human CCL13(Monocyte Chemotactic Protein 4) ELISA Kit
SKU: DEIA3268
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Serum, plasma, tissue homogenates and other biological fluids

Species Reactivity

Human

Detection Method

sELISA

Intended Use

CCL13 ELISA Kit allows for the in vitro quantitative determination of CCL13 concentrations in serum, plasma, tissue homogenates and other biological fluids.

Contents of Kit

Storage

2-8°C for 6 months

Precision

Intra-Assay: CV<8%
Inter-Assay: CV<10%

Detection Range

15.625-1000pg/ml

Sensitivity

< 9.375pg/ml

Standard Curve

Results of a typical standard operation of a CCL13 ELISA Kit are listed below. This standard curve was generated at our lab for demonstration purpose only. Users shall obtain standard curve as per experiment by themselves. (N/A=not applicable)

Citations

Have you cited DEIA3268 in a publication? Let us know and earn a reward for your research.

Background

MCP-4 is a cytokine from the CC chemokine family which is known as CCL13. Through binding to CCR2B and CCR3 receptors CCL13 activates chemotaxis which attracts monocytes as well as eosinophils basophils and T cells. CCL13 serves a key function in controlling immune responses and inflammation during allergic reactions like asthma. The chemokine CCL13 plays a role in directing monocytes to the vascular wall during atherosclerosis development.

Expression levels of CCL13 within tumor environments directly correlate with how immune cells infiltrate tumors and trigger immune responses. CCL13 expression in ovarian cancer indicates the presence of tertiary lymphoid structures and immune cell infiltration which positively impacts patient prognosis. The development of TLS in melanoma involves both B cells and T cells together and shows enhanced immunotherapy response and better patient survival rates. The CCL13/CXCR5 axis influences tumor cell survival and growth as well as their invasive potential through multiple pathways including PI3K/Akt and Raf/MEK/ERK along with integrin-β3/Src/FAK and DOCK2/Rac signaling.

Product Information

The Human CCL13 (Monocyte Chemotactic Protein 4) ELISA Kit enables in - vitro quantitative measurement of CCL13 in serum, plasma, tissue homogenates and other biological fluids. It uses sandwich ELISA technology. With pre - coated capture antibodies on 96 - well plates and biotin - conjugated detection antibodies, it has high sensitivity and specificity. The detection range is 15.625 - 1000pg/ml, and sensitivity is < 9.375pg/ml. Store at 2 - 8°C for 6 months. The assay involves sample preparation, reagent prep, incubation, washing and absorbance reading at 450nm to calculate CCL13 concentration.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Duodenal Mucosa of Patients With Type 1 Diabetes Shows Distinctive Inflammatory Profile and Microbiota

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Authors: Pellegrini, Silvia; Sordi, Valeria; Bolla, Andrea Mario; Saita, Diego; Ferrarese, Roberto; Canducci, Filippo; Clementi, Massimo; Invernizzi, Francesca; Mariani, Alberto; Bonfanti, Riccardo; Barera, Graziano; Testoni, Pier Alberto; Doglioni, Claudio; Bosi, Emanuele; Piemonti, Lorenzo

Abstract

Context: Increasing evidences suggest a correlation between gut and type 1 diabetes (T1D). Objective: The objective of this study is to evaluate the gut inflammatory profile and microbiota in patients with T1D compared with healthy control (CTRL) subjects and patients with celiac disease (CD) as gut inflammatory disease controls. Design/Setting/Participants: The inflammatory status and microbiome composition were evaluated in biopsies of the duodenal mucosa of patients with T1D (n = 19), in patients with CD (n = 19), and CTRL subjects (n = 16) recruited at San Raffaele Scientific Institute, in Milan, Italy, between 2009 and 2015. Main Outcome Measures: Inflammation was evaluated by gene expression study and immunohistochemistry. Microbiome composition was analyzed by 16S ribosomal RNA gene sequencing. Results: An increased expression of CCL13, CCL19, CCL22, CCR2, COX2, IL4R, CD68, PTX3, TNF alpha, and VEGFA was observed in patients with T1D compared with CTRL subjects and patients with CD. Immunohistochemical analysis confirmed T1D-specific inflammatory status compared with healthy and CD control tissues, mainly characterized by the increase of the monocyte/macrophage lineage infiltration. The T1D duodenal mucosal microbiome results were different from the other groups, with an increase in Firmicutes and Firmicutes/Bacteroidetes ratio and a reduction in Proteobacteria and Bacteroidetes. The expression of genes specific for T1D inflammation was associated with the abundance of specific bacteria in the duodenum. Conclusions: This study shows that duodenal mucosa in T1D presents disease-specific abnormalities in the inflammatory profile and microbiota. Understanding the mechanisms underlying these features is critical to disentangle the complex pathogenesis of T1D and to gain new perspectives for future therapies targeting the intestine.

Interferon-alpha restrains growth and invasive potential of hepatocellular carcinoma induced by hepatitis B virus X protein

WORLD JOURNAL OF GASTROENTEROLOGY

Authors: Yang, Jian-Qing; Pan, Guang-Dong; Chu, Guang-Ping; Liu, Zhen; Liu, Qiang; Xiao, Yi; Yuan, Lin

Abstract

AIM: To investigate the effects of interferon-alpha (IFN-alpha) to restrain the growth and invasive potential of hepatocellular carcinoma (HCC) induced by hepatitis B virus (HBV) X protein. METHODS: The pcDNA3.1-HBx plasmid was transfected into Chang cells by Lipofectamine In vitro, and Chang/HBx was co-cultured with IFN-alpha. Cell survival growth curve and clonogenicity assay were used to test the growth potential of Chang/pcDNA3.1, Chang/HBx and IFN-alpha-Chang/HBx in vitro. Growth assay in nude mice was used to detect the growth potential of Chang/pcDNA3.1, Chang/HBx and IFN-a-Chang/HBx In vivo. Wound healing and transwell migration assays were used to detect the invasive ability of Chang/pcDNA3.1, Chang/HBx and IFN-alpha-Chang/HBx. RESULTS: Compared with CCL13 cells transfected with pcDNA3.1, CCL13 with stable expression of hepatitis B virus X protein showed the characteristics of malignant cells with high capability of growth and invasion by detecting their growth curves, colony forming efficiency wound healing, transwell migration assays and growth assays in nude mice. Its capability of growth and invasion could be controlled by IFN-alpha. CONCLUSION: IFN-a can restrain the growth and invasive potential of HCC cells induced by HBx protein, which has provided an experimental basis for IFN-alpha therapy of HCC. (C) 2008 The WJG Press. All rights reserved.